ArticleMicrobiology spectrum2025
Population pharmacokinetics of vancomycin in non-extremely preterm neonates based on real-world studies: influence of daily fluid input and diuretics.
Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Systematic review and scoring-based selection of pharmacokinetic models for precision dosing of vancomycin in neonates and children.British journal of clinical pharmacology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
This study aimed to develop a population pharmacokinetics (PPK) model for vancomycin in non-extremely preterm neonates hospitalized in the neonatal intensive care unit (NICU), identify key factors affecting vancomycin pharmacokinetics in this patient population, and formulate an initial dosing protocol. A cohort of 126 neonates admitted to the NICU and treated with vancomycin at Northwest Women's and Children's Hospital from January 2019 to December 2023 were included in the study, resulting in the collection of 276 vancomycin concentration values. A PPK model for vancomycin was constructed using a nonlinear mixed-effects approach. The predictive power and stability of the final model were assessed through visual predictive checks, normalized prediction distribution errors, and bootstrapping. Serum creatinine (Scr) level, body weight, daily fluid input, and diuretic usage were identified as significant covariates affecting vancomycin clearance. Utilizing Monte Carlo simulations with the established model, initial recommended dosing regimens for neonates with varying Scr levels, daily fluid input, and diuretic use were estimated. The pharmacokinetic-pharmacodynamic model developed for vancomycin in non-extremely preterm neonates in the neonatal intensive care unit in this study may provide a theoretical reference for research on individualized medication. IMPORTANCE: A population pharmacokinetic model for vancomycin in neonatal intensive care unit neonates was developed. Daily fluid input and the use of diuretic agents were identified as new significant covariates influencing drug clearance. Based on these covariates, a dosing regimen was developed that provides clinicians with individualized dosing recommendations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.